Amneal Pharmaceuticals, Inc. (AMRX)
| Market Cap | 7.01B +96.8% |
| Revenue (ttm) | 3.20B +8.9% |
| Net Income | 133.30M +2,159.3% |
| EPS | 0.40 +2,380.0% |
| Shares Out | 348.30M |
| PE Ratio | 50.47 |
| Forward PE | 17.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,725,373 |
| Open | 19.45 |
| Previous Close | 19.45 |
| Day's Range | 19.30 - 20.43 |
| 52-Week Range | 11.30 - 21.68 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 24.29 (+20.61%) |
| Earnings Date | Nov 3, 2026 |
About AMRX
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and res... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for AMRX stock is "Strong Buy." The 12-month stock price target is $24.29, which is an increase of 20.61% from the latest price.
News
Amneal Pharmaceuticals price target raised to $28 from $25 at UBS
UBS raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $28 from $25 and keeps a Buy rating on the shares.
Amneal Pharmaceuticals price target raised to $25 from $24 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $24 and keeps an Overweight rating on the shares.
Amneal Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose 10% and adjusted EBITDA 30% YoY, prompting higher 2026 revenue, EBITDA, and EPS guidance. Kashiv integration and biosimilars anchor the growth plan, with 2030 revenue targeted at $4.3bn-$4.5bn.
Amneal Pharmaceuticals Slides: Q3 2026
Amneal Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Amneal Pharmaceuticals Earnings release: Q3 2026
Amneal Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Amneal Pharmaceuticals reports Q3 adjusted EPS 26c, consensus 24c
Reports Q3 revenue $863M, consensus $817.86M. “Amneal delivered another quarter of strong, broad-based performance, enabling us to increase our 2026 guidance once more. As we prepare to enter 2027, ou...
Amneal Pharmaceuticals raises FY26 adjusted EPS to $1.04-$1.08 from 96c-$1.06
FY26 consensus $1.03. Raises FY26 revenue view to $3.15B-$3.25B from $3.1B-$3.2B, consensus $3.16B.
Amneal Reports Third Quarter 2026 Financial Results
– Q3 2026 Net Revenue of $863 million ; GAAP Net Loss of $22 million ; Diluted Loss per Share of $(0.06) – – Adjusted EBITDA of $207 million ; Adjusted Diluted EPS of $0.26 – – Updating 2026 Full Yea...
Amneal Pharmaceuticals price target raised to $24 from $21 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $24 from $21 and keeps a Buy rating on the shares.
Amneal Pharmaceuticals price target raised to $24 from $22 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $24 from $22 and keeps an Overweight rating on the shares.
Amneal to Report Third Quarter 2026 Results on November 3, 2026
BRIDGEWATER, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced it will report third quarter 2026 financial results on Tue...
Amneal Pharmaceuticals initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating and $27 price target The firm believes Amneal is at a “fundamental inflection.” The company’s “differentiated”...
Amneal Pharmaceuticals announces FDA approval and launch of Lanreotide
Amneal Pharmaceuticals (AMRX) “announced that the U.S. Food and Drug Administration has approved its lanreotide injection, 120 mg/0.5 mL, in a sterile, single-dose prefilled syringe. The product refer...
Amneal Announces FDA Approval and Launch of Lanreotide Injection
- Expands complex injectables portfolio with important long-acting oncology treatment - Immediate commercial launch supported by in-house production
Amneal Pharmaceuticals price target raised to $20 from $16 at Barclays
Barclays raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $20 from $16 and keeps an Overweight rating on the shares. The pending gLanreotide approval, which is expected any…
Leerink bullish on Amneal Pharmaceuticals, initiates with an Outperform
As previously reported, Leerink initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating. The firm names the stock a Top Pick, citing Affordable Medicines momentum, biosimilars up...
Amneal Pharmaceuticals initiated with an Outperform at Leerink
Leerink initiated coverage of Amneal Pharmaceuticals (AMRX) with an Outperform rating and $23 price target
Amneal Pharmaceuticals resumed with an Overweight at JPMorgan
JPMorgan resumed coverage of Amneal Pharmaceuticals (AMRX) with an Overweight rating and price target of $22, up from $18, following a period of restriction. The firm views the company as…
Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader
Establishes an integrated global platform spanning biosimilar R&D, manufacturing and commercialization Adds a major long-term growth pillar and extends Amneal's growth profile into the 2030s BRIDGEWA...
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
UBS analyst Ashwani Verma raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares. Amneal’s strong Q2 beat and…
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
UBS raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares.
Amneal Pharmaceuticals price target raised to $25 from $23 at UBS
UBS raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $25 from $23 and keeps a Buy rating on the shares. Amneal’s strong Q2 beat and raised outlook create…
Amneal Pharmaceuticals Transcript: EGM 2026
Stockholders approved the acquisition of Kashiv BioSciences, LLC and the issuance of new shares to sellers, with both proposals receiving unanimous board support and no questions from stakeholders. Official results will be announced after verification.
Amneal Pharmaceuticals price target raised to $21 from $19 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Amneal Pharmaceuticals (AMRX) to $21 from $19 and keeps a Buy rating on the shares.
Amneal Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 saw double-digit revenue and profit growth, driven by strong performance in affordable medicines, specialty, and biosimilars. The company raised its full-year outlook and is set to close the Kashiv acquisition, expanding its biosimilar platform and pipeline.